Robin Pakenham

Robin Pakenham is an experienced professional, currently serving as the Chief Operating and Financial Officer at Isomab Ltd, focusing on moving the patented antibody Vexobicizumab from lab to clinical trials for peripheral arterial disease. With a background in various financial roles in biotech, gene therapy, and technology companies, Robin has a strong track record of success in strategic financial management and program development. Known for accomplishments such as managing complex due diligence processes, debt raises, and business plan development, Robin's expertise in finance and operations is highly valued in the industry.